At the center of your product’s value story is a patient—THE patient. We draw on a deep understanding of the rare and underserved disease space and expertise in positioning highly innovative pharmaceuticals to drive home the disease burden in a way payers can’t ignore. And we keep the patient front and center in the payer’s mind. Always.
HTA & Value Dossiers
Value and Access
Pharmaceutical Communications
Compelling. Tailored. Evidence-based.
Show payers the value.
Build on a rock-solid foundation with fit-for-purpose Value & Access Dossiers.
We’ve reinvented the clunky and expansive Global Value Dossier into a sleek, fit-for-purpose solution: the Stratenym Core Value Dossier (CVD).
Intelligently designed to address your need for consistency in HTA submissions across regions while streamlining the transfer to reimbursement authority templates, our CVD eases the workload on your team by making the entire reimbursement process more efficient.
It’s showtime—don’t hand your HTA and Reimbursement Submissions over to the understudy!
At the finish line, you want the best health technology assessment consultancy in your corner. You, your product, and patients deserve the best. Our experts have prepared submissions for almost every HTA body in Europe, and many beyond, as well as AMCP dossiers and both public and private payer submissions for the Canadian market. With 30+ submissions in the past four years, you’re in good hands with Stratenym.
Supercharge your market access communications.
We’re your partner from beginning to end, and we love the challenge of helping you achieve market access success.
So, let us do the heavy lifting.
